MedTrace Logo

SLNB After Neoadjuvant Treatment in Node Positive Patients

NCT03833960 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 65

Last updated 2023-12-19

No results posted yet for this study

Summary

From May 2016 till May 2018 all breast cancer patients with operable disease submitted to surgery after neoadjuvant treatment would be divided in four groups considering initially clinical axillary stage, axillary procedure that was done, axillary response to preoperative systemic treatment and pathological axillary stage.

In first postoperative year all patients will be monitored for appearance of locoregional and distant recurrence.

Conditions

  • Sentinel Lymph Node Biopsy
  • Locoregional Neoplasm Recurrence
  • Progression, Disease

Sponsors & Collaborators

  • Clinical Hospital Center Rijeka

    lead OTHER

Principal Investigators

  • Ana C Car Peterko · Clinical Hospital Center Rijeka

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2019-05-31
Completion
2019-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03833960 on ClinicalTrials.gov